Neutralizing monoclonal antibodies (nmAbs) showed no clear benefit for hospitalized COVID-19 patients. This study investigated the dynamics of virologic and immunologic biomarkers in patients randomized to nmAb versus placebo in the Therapeutics for Inpatients with COVID-19 (TICO) trials. Longitudinal differences in plasma nucleocapsid antigen (N-Ag), anti-nucleocapsid antibody, C-reactive protein, interleukin-6, and D-dimer were analyzed. NmAb resulted in 20% lower plasma N-Ag levels compared to placebo (P < .001), with a steeper decline. However, no differences were observed in other biomarkers or the day 5 pulmonary ordinal scale. The study suggests an antiviral effect of nmAb on plasma N-Ag, without blunting the antibody response, but no impact on systemic inflammation or clinical status.
Publisher
The Journal of Infectious Diseases
Published On
Nov 09, 2023
Authors
Tomas O Jensen, Greg A Grandits, Mamta K Jain, Thomas A Murray, Birgit Grund, Kathryn Shaw-Saliba, Michael A Matthay, Mahsa Abassi, Magdalena Ardelt, Jason V Baker, Peter Chen, Robin L Dewar, Anna L Goodman, Timothy J Hatlen, Helene C Highbarger, Mark Holodniy, Perrine Lallemand, Sylvain Laverdure, Bradley G Leshnower, David Looney, Charalampos D Moschopoulos, Henry Mugerwa, Daniel D Murray, Eleftherios Mylonakis, Stephanie Nagy-Agren, M Tauseef Rehman, Adam Rupert, Randy A Stevens, Stuart Turville, Amy Weintrob, Katherine Wick, Jens Lundgren, Emily Ray Ko
Tags
COVID-19
neutralizing monoclonal antibodies
plasma nucleocapsid antigen
biomarkers
systemic inflammation
clinical outcomes
virologic dynamics
Related Publications
Explore these studies to deepen your understanding of the subject.
